Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

The voicemail — which sounds something like an automated message — begins, “This is a critical voter alert for residents of ...

Bakersfield City Council candidate Mike Madrigal faces calls to drop out of the race over an allegation that he assaulted a ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...

Madrigal Pharmaceuticals' Rezdiffra for NASH shows strong early demand, positioning the company as a market leader. Read why ...

Shares of companies developing therapies for the liver disease metabolic steatohepatitis, or MASH, are rallying after Novo Nordisk (NVO) said ...

Family members of a former girlfriend of B City Council Ward 5 candidate Mike Madrigal are calling for him to drop out of the ...

Explaining that social media “is getting hammered by disinformation,” Madrigal and the video are part of a campaign by CALÓ ...